Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
Rhea-AI Summary
Senti Biosciences (Nasdaq: SNTI) announced that CEO Timothy Lu will present at the AACR Annual Meeting 2026 on April 17, 2026, in San Diego. The educational session, “Engineered NK Cells: From Innate Immunity to Clinical Innovation,” will highlight advances in Senti’s logic-gated SENTI-202 cell therapy and recent clinical trial results in relapsed/refractory acute myeloid leukemia.
The presentation will run 3:00–4:30 PM PT and will discuss how Logic Gates aim to increase therapeutic windows and improve precision in oncology cell therapies.
Positive
- None.
Negative
- None.
News Market Reaction – SNTI
In the Apr 13 session, SNTI gained 3.26%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Scientific publication | Positive | +3.3% | Cell Systems paper on NOT-gated CAR circuits showing selective tumor killing. |
| Mar 27 | Earnings and update | Negative | -10.4% | Full-year 2025 results with significant net loss alongside RMAT and pipeline updates. |
| Mar 23 | Conference presentation | Positive | -2.2% | Announcement of SENTI-202 data presentations at Innate Killer conference. |
| Mar 03 | Investor conference | Neutral | +2.1% | CEO presentation at Leerink Partners healthcare conference with webcast access. |
| Feb 24 | Investor conference | Positive | +7.1% | TD Cowen conference talk on Gene Circuit platform, pipeline, and partnerships. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference and presentation news has often yielded modestly positive reactions, but one recent scientific conference update saw a small negative divergence.
Over the past few months, Senti Biosciences has highlighted both platform science and corporate visibility. A Cell Systems publication on NOT-gated CAR circuits on Apr 1, 2026 coincided with a +3.31% move. Multiple conference presentations (Leerink, TD Cowen, Innate Killer) produced mixed but generally positive single-day reactions, including a +7.08% move on Feb 24, 2026. The latest earnings and corporate update on Mar 27, 2026 paired significant losses with RMAT and clinical progress, followed by a -10.36% reaction.
Key Terms
engineered nk cells medical
logic-gated medical
cell therapy medical
t cell engagers medical
antibody-drug conjugates medical
acute myeloid leukemia medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, Co-Founder and Chief Executive Officer of Senti, will present at the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.
Dr. Lu will participate in an educational session titled “Engineered NK Cells: From Innate Immunity to Clinical Innovation.” The session will highlight advances in the development of Senti’s engineered Logic-Gated SENTI-202 cell therapy and the broader potential for Logic Gates to address a wide range of unmet needs in oncology.
Presentation Details:
- Session Title: Engineered NK Cells: From Innate Immunity to Clinical Innovation
- Session Type: Educational Session
- Presenter: Timothy Lu, Co-Founder & CEO, Senti Biosciences
- Date: Friday, April 17, 2026
- Time: 3:00 – 4:30 PM PT
- Location: AACR Annual Meeting 2026, San Diego, CA
“We are honored to contribute to this important educational session at AACR,” said Dr. Lu. “Our Logic-Gated cell therapies selectively kill cancer cells while protecting healthy cells. Enhanced therapeutic windows from Logic Gates enable the treatment of cancers for which conventional single-target biologics, such as T cell engagers and antibody-drug conjugates, and conventional single-target cell therapies are unable to perform. We look forward to sharing insights from our recent SENTI-202 clinical trial results in relapsed/refractory acute myeloid leukemia and other applications of our Logic Gates to improve precision and efficacy for cancer therapies.”
The AACR Annual Meeting is one of the leading global conferences for cancer research, bringing together scientists, clinicians, and industry leaders to discuss the latest advances in cancer science and medicine. For more information, please visit the conference website here.
About Senti Bio
Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
